Skip to main content
Top
Published in: Clinical Rheumatology 9/2012

01-09-2012 | Original Article

The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis

Authors: Gabor Papp, Sandor Barath, Andrea Szegedi, Peter Szodoray, Margit Zeher

Published in: Clinical Rheumatology | Issue 9/2012

Login to get access

Abstract

In the study, we investigated the influence of extracorporeal photochemotherapy (ECP) on lymphocyte activation and cell death by determining CD95, Annexin V, CD69 and human leukocyte antigen (HLA)-DR expression on circulating T and B cells in systemic sclerosis (SSc) patients and assessed their changes after ECP therapies. Moreover, we evaluated the relationship between lymphocyte activation and the observed changes in immunoregulatory functions following ECP treatments. We enrolled 19 SSc patients, who received 12 ECP treatments in total. Blood samples were taken prior to the first therapy and 6 weeks after each cycle. Samples were also obtained from 16 healthy controls. Lymphocyte subgroups were quantified by flow cytometry. Initially, patients had higher numbers and percentages of peripheral CD95+ T cells, but not CD95+ B cells, compared to control values. After ECP treatments, values of CD95+ T cells decreased and became similar to controls. Annexin V expression on T and B cells did not change during the therapy. We observed a significant negative correlation between the changes in percentages of peripheral CD95+ T cells and CD4+CD25+ Treg cells. Although neither early-activated (CD69+) nor late-activated (HLA-DR+) T lymphocytes showed significant changes after ECP, clear negative correlations developed between them and the functional ability of CD4+CD25+ Treg cells after the last treatment. Our results indicate that the initial increase of CD95+ expression in SSc presumably reflects a physiological response to the pronounced autoimmune processes, which can be effectively attenuated by the restoration of regulative T cell numbers and functions as the result of ECP therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573–1576PubMed
2.
go back to reference Papp G, Horvath IF, Barath S, Gyimesi E, Sipka S, Szodoray P, Zeher M (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40:205–210PubMedCrossRef Papp G, Horvath IF, Barath S, Gyimesi E, Sipka S, Szodoray P, Zeher M (2011) Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 40:205–210PubMedCrossRef
3.
go back to reference Szodoray P, Papp G, Nakken B, Harangi M, Zeher M (2010) The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmun Rev 9:459–464PubMedCrossRef Szodoray P, Papp G, Nakken B, Harangi M, Zeher M (2010) The molecular and clinical rationale of extracorporeal photochemotherapy in autoimmune diseases, malignancies and transplantation. Autoimmun Rev 9:459–464PubMedCrossRef
4.
go back to reference Bladon J, Taylor PC (2006) Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci 43:85–94PubMedCrossRef Bladon J, Taylor PC (2006) Extracorporeal photopheresis: a focus on apoptosis and cytokines. J Dermatol Sci 43:85–94PubMedCrossRef
6.
go back to reference Papp G, Horvath IF, Barath S, Gyimesi E, Vegh J, Szodoray P, Zeher M (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142:150–159PubMedCrossRef Papp G, Horvath IF, Barath S, Gyimesi E, Vegh J, Szodoray P, Zeher M (2012) Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 142:150–159PubMedCrossRef
7.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202–205PubMed
8.
go back to reference Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P Jr, Szegedi G, Nakken B, Zeher M (2008) Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 37:205–212PubMedCrossRef Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P Jr, Szegedi G, Nakken B, Zeher M (2008) Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 37:205–212PubMedCrossRef
9.
go back to reference Kessel A, Rosner I, Rozenbaum M, Zisman D, Sagiv A, Shmuel Z, Sabo E, Toubi E (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. J Clin Immunol 24:30–36PubMedCrossRef Kessel A, Rosner I, Rozenbaum M, Zisman D, Sagiv A, Shmuel Z, Sabo E, Toubi E (2004) Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B. J Clin Immunol 24:30–36PubMedCrossRef
10.
go back to reference Stummvoll GH, Aringer M, Smolen JS, Köller M, Kiener HP, Steiner CW, Bohle B, Knobler R, Graninger WB (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39:1341–1350CrossRef Stummvoll GH, Aringer M, Smolen JS, Köller M, Kiener HP, Steiner CW, Bohle B, Knobler R, Graninger WB (2000) Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 39:1341–1350CrossRef
11.
go back to reference Paulsen M, Janssen O (2011) Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal 9:7PubMedCrossRef Paulsen M, Janssen O (2011) Pro- and anti-apoptotic CD95 signaling in T cells. Cell Commun Signal 9:7PubMedCrossRef
12.
go back to reference Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545–1556PubMedCrossRef Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR (1995) Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1545–1556PubMedCrossRef
Metadata
Title
The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis
Authors
Gabor Papp
Sandor Barath
Andrea Szegedi
Peter Szodoray
Margit Zeher
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 9/2012
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-012-2000-x

Other articles of this Issue 9/2012

Clinical Rheumatology 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine